Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice

  1. Marina Kovalenko
  2. Serkan Erdin
  3. Marissa A Andrew
  4. Jason St Claire
  5. Melissa Shaughnessey
  6. Leroy Hubert
  7. João Luís Neto
  8. Alexei Stortchevoi
  9. Daniel M Fass
  10. Ricardo Mouro Pinto
  11. Stephen J Haggarty
  12. John H Wilson
  13. Michael E Talkowski
  14. Vanessa C Wheeler  Is a corresponding author
  1. Massachusetts General Hospital, United States
  2. Massachusetts General Hospital/Broad Institute, United States
  3. Baylor College of Medicine, United States
  4. Massachusetts General Hospital, Harvard Medical School, United States

Abstract

Somatic expansion of the Huntington's disease (HD) CAG repeat drives the rate of a pathogenic process ultimately resulting in neuronal cell death. Although mechanisms of toxicity are poorly delineated, transcriptional dysregulation is a likely contributor. To identify modifiers that act at the level of CAG expansion and/or downstream pathogenic processes, we tested the impact of genetic knockout, in HttQ111 mice, of Hdac2 or Hdac3 in medium-spiny striatal neurons that exhibit extensive CAG expansion and exquisite disease vulnerability. Both knockouts moderately attenuated CAG expansion, with Hdac2 knockout decreasing nuclear huntingtin pathology. Hdac2 knockout resulted in a substantial transcriptional response that included modification of transcriptional dysregulation elicited by the HttQ111 allele, likely via mechanisms unrelated to instability suppression. Our results identify novel modifiers of different aspects of HD pathogenesis in MSNs and highlight a complex relationship between the expanded Htt allele and Hdac2 with implications for targeting transcriptional dysregulation in HD.

Data availability

RNA-Seq data is deposited in GEO, under the accession number GSE148440

The following data sets were generated

Article and author information

Author details

  1. Marina Kovalenko

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  2. Serkan Erdin

    Center for Genomic Medicine/Program in Medical and Population Genetics, Massachusetts General Hospital/Broad Institute, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6587-2625
  3. Marissa A Andrew

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  4. Jason St Claire

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  5. Melissa Shaughnessey

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  6. Leroy Hubert

    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States
    Competing interests
    No competing interests declared.
  7. João Luís Neto

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0863-158X
  8. Alexei Stortchevoi

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  9. Daniel M Fass

    Center for Genomic Medicine, Massachusetts General Hospital, Boston, United States
    Competing interests
    Daniel M Fass, D.M.F. is a member of the scientific advisory board of Psy Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0018-8093
  10. Ricardo Mouro Pinto

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    Competing interests
    No competing interests declared.
  11. Stephen J Haggarty

    Chemical Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    Stephen J Haggarty, S.J.H. is a member of the scientific advisory board of Psy Therapeutics, Frequency Therapeutics and Souvien Therapeutics, and former member of the scientific advisory board of Rodin Therapeutics that is focused on HDAC2 inhibitors, none of whom were involved in the present study. S.J.H. has also received speaking or consulting fees from Amgen, AstraZeneca, Biogen, Merck, Regenacy Pharmaceuticals, as well as sponsored research or gift funding from AstraZeneca, JW Pharmaceuticals, and Vesigen unrelated to the content of this manuscript. His financial interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7872-168X
  12. John H Wilson

    Verna and Marrs McLean Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States
    Competing interests
    No competing interests declared.
  13. Michael E Talkowski

    Center for Genomic Medicine/Program in Medical and Population Genetics, Massachusetts General Hospital/Broad Institute, Boston, United States
    Competing interests
    No competing interests declared.
  14. Vanessa C Wheeler

    Center for Genomic Medicine; Department of Neurology, Massachusetts General Hospital, Boston, United States
    For correspondence
    wheeler@helix.mgh.harvard.edu
    Competing interests
    Vanessa C Wheeler, V.C.W is a scientific advisory board member of Triplet Therapeutics, a company developing new therapeutic approaches to address triplet repeat disorders such Huntington's disease and Myotonic Dystrophy and of LoQus23 Therapeutics. Her financial interests in Triplet Therapeutics, were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2619-589X

Funding

Huntington Society of Canada (New Pathways Research Grant)

  • Vanessa C Wheeler

National Institutes of Health (NS049206)

  • Vanessa C Wheeler

Huntington's Disease Society of America (Berman Topper Career Development Award)

  • Ricardo Mouro Pinto

National Institutes of Health (GM38219)

  • John H Wilson

National Institutes of Health (EY11731)

  • John H Wilson

National Institutes of Health (1F3HG004918)

  • Leroy Hubert

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health under an approved protocol (2009N000216) of the Massachusetts General Hospital Subcommittee on Research Animal Care.

Copyright

© 2020, Kovalenko et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,187
    views
  • 305
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Marina Kovalenko
  2. Serkan Erdin
  3. Marissa A Andrew
  4. Jason St Claire
  5. Melissa Shaughnessey
  6. Leroy Hubert
  7. João Luís Neto
  8. Alexei Stortchevoi
  9. Daniel M Fass
  10. Ricardo Mouro Pinto
  11. Stephen J Haggarty
  12. John H Wilson
  13. Michael E Talkowski
  14. Vanessa C Wheeler
(2020)
Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice
eLife 9:e55911.
https://doi.org/10.7554/eLife.55911

Share this article

https://doi.org/10.7554/eLife.55911

Further reading

    1. Genetics and Genomics
    2. Neuroscience
    Monique Marylin Alves de Almeida, Yves De Repentigny ... Rashmi Kothary
    Research Article

    Spinal muscular atrophy (SMA) is caused by mutations in the Survival Motor Neuron 1 (SMN1) gene. While traditionally viewed as a motor neuron disorder, there is involvement of various peripheral organs in SMA. Notably, fatty liver has been observed in SMA mouse models and SMA patients. Nevertheless, it remains unclear whether intrinsic depletion of SMN protein in the liver contributes to pathology in the peripheral or central nervous systems. To address this, we developed a mouse model with a liver-specific depletion of SMN by utilizing an Alb-Cre transgene together with one Smn2B allele and one Smn1 exon 7 allele flanked by loxP sites. Initially, we evaluated phenotypic changes in these mice at postnatal day 19 (P19), when the severe model of SMA, the Smn2B/- mice, exhibit many symptoms of the disease. The liver-specific SMN depletion does not induce motor neuron death, neuromuscular pathology or muscle atrophy, characteristics typically observed in the Smn2B/- mouse at P19. However, mild liver steatosis was observed, although no changes in liver function were detected. Notably, pancreatic alterations resembled that of Smn2B/-mice, with a decrease in insulin-producing β-cells and an increase in glucagon-producingα-cells, accompanied by a reduction in blood glucose and an increase in plasma glucagon and glucagon-like peptide (GLP-1). These changes were transient, as mice at P60 exhibited recovery of liver and pancreatic function. While the mosaic pattern of the Cre-mediated excision precludes definitive conclusions regarding the contribution of liver-specific SMN depletion to overall tissue pathology, our findings highlight an intricate connection between liver function and pancreatic abnormalities in SMA.

    1. Computational and Systems Biology
    2. Genetics and Genomics
    Jia-Ying Su, Yun-Lin Wang ... Chien-Ling Lin
    Research Article

    Untranslated regions (UTRs) contain crucial regulatory elements for RNA stability, translation and localization, so their integrity is indispensable for gene expression. Approximately 3.7% of genetic variants associated with diseases occur in UTRs, yet a comprehensive understanding of UTR variant functions remains limited due to inefficient experimental and computational assessment methods. To systematically evaluate the effects of UTR variants on RNA stability, we established a massively parallel reporter assay on 6555 UTR variants reported in human disease databases. We examined the RNA degradation patterns mediated by the UTR library in two cell lines, and then applied LASSO regression to model the influential regulators of RNA stability. We found that UA dinucleotides and UA-rich motifs are the most prominent destabilizing element. Gain of UA dinucleotide outlined mutant UTRs with reduced stability. Studies on endogenous transcripts indicate that high UA-dinucleotide ratios in UTRs promote RNA degradation. Conversely, elevated GC content and protein binding on UA dinucleotides protect high-UA RNA from degradation. Further analysis reveals polarized roles of UA-dinucleotide-binding proteins in RNA protection and degradation. Furthermore, the UA-dinucleotide ratio of both UTRs is a common characteristic of genes in innate immune response pathways, implying a coordinated stability regulation through UTRs at the transcriptomic level. We also demonstrate that stability-altering UTRs are associated with changes in biobank-based health indices, underscoring the importance of precise UTR regulation for wellness. Our study highlights the importance of RNA stability regulation through UTR primary sequences, paving the way for further exploration of their implications in gene networks and precision medicine.